Divalent siRNA Clinical Trial Is Now Recruiting

Key Takeaways

• 15 symptomatic patients receive a single dose of PrP‑siRNA
• Dose levels: 50 mg, 100 mg, 200 mg, escalated sequentially
• Observational arm provides non‑treated comparator without placebo
• Single dose expected to lower brain PrP for months in mice
• Trial data will guide future dosing schedules and biomarker use

Pulse Analysis

Prion disease remains one of the most lethal neurodegenerative conditions, with no approved disease‑modifying treatments. Researchers at the Broad Institute and UMass have engineered a divalent small interfering RNA (siRNA) that targets the prion protein (PrP) mRNA, achieving sustained knock‑down in humanized mouse models. By leveraging advances in RNA therapeutics and a decade of preclinical work, the new investigational drug, 2439‑s4, entered a first‑in‑human trial after the FDA cleared an IND application, marking a pivotal step toward translating molecular insights into patient benefit.

The trial adopts a single‑ascending‑dose design, enrolling fifteen symptomatic participants who will receive one of three dose levels—50 mg, 100 mg, or 200 mg—based on safety data from animal toxicology studies. Participants undergo intensive monitoring, including lumbar puncture, blood draws, MRI, and cognitive assessments over a 24‑week follow‑up. To address the ethical and logistical challenges of placebo use in a rare, rapidly progressing disease, the study incorporates an observational arm, allowing comparable data collection from untreated patients. This hybrid approach aims to generate robust safety and pharmacodynamic signals while preserving patient access to experimental therapy.

Beyond its immediate goals, the trial sets a precedent for rare‑disease drug development. Success would validate RNA‑based PrP reduction as a therapeutic strategy and provide critical biomarkers, recruitment benchmarks, and endpoint data for future larger trials. Even if the siRNA does not advance, the shared data and methodological innovations—such as the observational comparator—will enrich the limited knowledge base for prion disease research and could accelerate the design of trials for other neurodegenerative disorders. The initiative underscores the importance of iterative, collaborative science in tackling diseases with high unmet need.